share_log

Verona Pharma And Ritedose Partner To Deliver First-In-Class COPD Drug, Ohtuvayre

Benzinga ·  Sep 17 20:31

-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of COPD.

COLUMBIA, S.C., Sept. 17, 2024 /PRNewswire/ -- The Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona Pharma plc (NASDAQ:VRNA) as the development and manufacturing partner of Ohtuvayre, a new novel product for Chronic Obstructive Pulmonary Disease (COPD).

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment